Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

An announcement from Neurocrine ( ($NBIX) ) is now available. On January 24, 2025, Neurocrine Biosciences announced an amendment to its Exclusive ...

Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced ...

Atomi Financial Group Inc. trimmed its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering, becoming the first sizeable Chinese firm to pursue a listing in the U.S. this year.

BioLife Plasma Services LP and Takeda Pharmaceuticals USA Inc. enabled third parties to intercept the personal information of ...

Ballentine Partners LLC grew its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 24.3% in the 4th quarter, according to the company in its most recent filing ...

Japan’s market growth accelerates through dynamic clinical partnerships, biologic breakthroughs, and automated facilities.

The Innovation Capability Centre plans to hire 750 professionals, including software engineers, data scientists, and ...

Health Canada has granted market authorisation to Takeda Canada for FRUZAQLA (fruquintinib) capsules to treat adults with ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...